{"pageContent": "Objectives: To assess if prostate-specific antigen (PSA) nadir is an independent predictor of treatment failure and disease-free survival after high-intensity focussed ultrasound (HIFU) therapy for localised prostate cancer as defined by the new ASTRO criteria.", "metaData": {"source": "The ProMotion LMU dataset, prostate intra-fraction motion recorded by transperineal ultrasound\nhttps://pubmed.ncbi.nlm.nih.gov/31712658/"}}